Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...

Apogee Therapeutics (NASDAQ:APGE) stock fell on Monday despite the announcement that it met its main goal in part A of its ...

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch ...

AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and ...

A focused update to AAD’s adult AD guidelines recommends tapinarof, roflumilast, lebrikizumab, and nemolizumab based on ...

Apogee Therapeutics shares soared in premarket trading Monday after the company said it received positive trial data for its atopic dermatitis treatment. Shares traded 36% higher ahead of the morning ...

Apogee Therapeutics’ anti-IL-13 antibody has been tied to a 71% reduction in eczema severity after 16 weeks, hitting the main ...

In this video, Robert J. Smith, MD, discusses the many treatment options available to patients with atopic dermatitis.

Young patients with atopic dermatitis prioritize different treatment goals and have varying preferences from their caregivers.

Spongiotic dermatitis describes skin inflammation that causes swelling, redness, and itching. It's most often associated with ...